Impact of Stereotactic Body Radiotherapy on Thrombin Generation and Platelet Aggregation in Patients with Non-Small Cell Lung Cancer

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2023 Nov 27

PMID 38009051

Authors

Kristian Kirkelund Bentsen

Johanne Andersen Hojbjerg

Pernille Just Vinholt

Olfred Hansen

Anne-Mette Hvas

Stefan Starup Jeppesen

Affiliations

Soon will be listed here.

Abstract

Patients with localized non-small cell lung cancer (NSCLC) considered unfit for surgery are at substantially increased risk of venous thromboembolism. Radiotherapy may further increase this risk. We aim to investigate the impact of stereotactic body radiotherapy (SBRT) on thrombin generation and platelet aggregation. We included 110 patients with localized NSCLC treated with SBRT. Blood samples were obtained prior to SBRT, immediately after SBRT completion, and 4-6 weeks following SBRT. and thrombin generations were analyzed using a calibrated automated thrombogram and commercial enzyme-linked immunosorbent assays. Platelet aggregation was evaluated using multiple electrode aggregometry. No significant differences were found in or thrombin generation between blood samples before and immediately after SBRT treatment. Platelet aggregation was lower immediately after SBRT than before SBRT (TRAP: = 0.04 and ASPI: = 0.02) but remained within the reference interval. SBRT did not affect and thrombin generation or platelet aggregation. SBRT did not cause prothrombotic changes in the coagulation in this study population of SBRT-treated patients with localized NSCLC.

References

Ay C, Pabinger I, Cohen A . Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost. 2016; 117(2):219-230. DOI: 10.1160/TH16-08-0615. View

Janssen-Heijnen M, Schipper R, Razenberg P, Crommelin M, Coebergh J . Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998; 21(2):105-13. DOI: 10.1016/s0169-5002(98)00039-7. View

Khorana A, Francis C, Culakova E, Kuderer N, Lyman G . Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3):632-4. DOI: 10.1111/j.1538-7836.2007.02374.x. View

Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J . Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis. Clin Appl Thromb Hemost. 2007; 14(3):279-85. DOI: 10.1177/1076029607309176. View

Riedl J, Pabinger I, Ay C . Platelets in cancer and thrombosis. Hamostaseologie. 2013; 34(1):54-62. DOI: 10.5482/HAMO-13-10-0054. View

Pedersen O, Larsen M, Grove E, van Kooten Niekerk P, Bonlokke S, Nissen P . Platelet characteristics in patients with essential thrombocytosis. Cytometry B Clin Cytom. 2018; 94(6):918-927. DOI: 10.1002/cyto.b.21642. View

Cohen A, Katholing A, Rietbrock S, Bamber L, Martinez C . Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 2016; 117(1):57-65. DOI: 10.1160/TH15-08-0686. View

Noble S . Cancer-associated thrombosis and palliative care: an interview with Simon Noble. Future Oncol. 2016; 13(1):13-17. DOI: 10.2217/fon-2016-0435. View

Malte A, Hojbjerg J, Larsen J . Platelet Parameters as Biomarkers for Thrombosis Risk in Cancer: A Systematic Review and Meta-analysis. Semin Thromb Hemost. 2023; 50(3):360-383. DOI: 10.1055/s-0043-1764381. View

10.

Bochsen L, Johansson P, Kristensen A, Daugaard G, Ostrowski S . The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis. 2011; 22(3):167-75. DOI: 10.1097/MBC.0b013e3283424911. View

11.

Kirkelund Bentsen K, Hansen O, Ryg J, Giger A, Starup Jeppesen S . Combination of the G-8 Screening Tool and Hand-Grip Strength to Predict Long-Term Overall Survival in Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy. Cancers (Basel). 2021; 13(13). PMC: 8269387. DOI: 10.3390/cancers13133363. View

12.

Bahtiyar N, Onaran I, Aydemir B, Baykara O, Toplan S, Agaoglu F . Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy. Oncol Lett. 2018; 16(4):4745-4753. PMC: 6144890. DOI: 10.3892/ol.2018.9167. View

13.

Lincz L, Gupta S, Wratten C, Kilmurray J, Nash S, Seldon M . Thrombin generation as a predictor of radiotherapy induced skin erythema. Radiother Oncol. 2008; 90(1):136-40. DOI: 10.1016/j.radonc.2008.10.002. View

14.

Rubak P, Villadsen K, Hvas A . Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry. Thromb Res. 2012; 130(3):420-3. DOI: 10.1016/j.thromres.2012.06.017. View

15.

Lloyd A, Dewilde S, Noble S, Reimer E, Lee A . What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life?. Value Health. 2018; 21(4):449-455. DOI: 10.1016/j.jval.2017.09.015. View

16.

Vibede E, Hvas C, Tonnesen E, Hvas A . The effect of fresh frozen plasma in critically ill patients. Acta Anaesthesiol Scand. 2017; 61(5):492-501. DOI: 10.1111/aas.12885. View

17.

Begtrup K, Hojbjerg J, Offersen B, Hvas A . Adjuvant radiotherapy does not affect hemostasis. Platelets. 2018; 30(3):387-395. DOI: 10.1080/09537104.2018.1448378. View

18.

Dutkowska A, Antczak A . Comorbidities in lung cancer. Pneumonol Alergol Pol. 2016; 84(3):186-92. DOI: 10.5603/PiAP.2016.0022. View

19.

Engbers M, van Hylckama Vlieg A, Rosendaal F . Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010; 8(10):2105-12. DOI: 10.1111/j.1538-7836.2010.03986.x. View

20.

Mouthon M, Vereycken-Holler V, Van der Meeren A, Gaugler M . Irradiation increases the interactions of platelets with the endothelium in vivo: analysis by intravital microscopy. Radiat Res. 2003; 160(5):593-9. DOI: 10.1667/3068. View